Methylphenidate for ADHD

As monotherapy or in combination with methylphenidate for ADHD with conduct disorder or oppositional defiant disorder, may improve aggression, oppositional, and conduct disorder symptoms... 

For the expert, can combine immediate release formulation with a sustained release formulation of d,l-methylphenidate for ADHD... 

At low doses, both psychostimulants could theoretically stimulate tonic, extracellular levels of monoamines, and the small increase in steady state levels would produce feedback inhibition of further release by stimulating presynaptic autoreceptors. While this mechanism is clearly an important one for the normal regulation of monoamine neurotransmission, there is no direct evidence to support the notion that the doses used clinically to treat ADHD are low enough to have primarily presynaptic effects. However, alterations in phasic dopamine release could produce net reductions in dopamine release under putatively altered tonic dopaminergic conditions that might occur in ADHD and that might explain the beneficial effects of methylphenidate in ADHD. 

Atomoxetine is the most recent addition to the ADHD armamentarium in both children and adults. In clinical studies, atomoxetine has demonstrated superior efficacy over placebo and equivalent efficacy when compared with a suboptimal immediate-release methylphenidate dose.17 20 However, it is not clear whether atomoxetine is superior to typical methylphenidate doses or other stimulant formulations. Atomoxetine may be used as a second- or third-line medication for ADHD. 

Methylphenidate and amphetamines have been used for ADHD management for many years but due to abuse potentials, these drugs are controlled substances." " Lisdexamfetamine itself is inactive and acts as a prodrug to dextroamphetamine upon cleavage of the lysine portion of the molecule. It was developed for the intention of creating a longer-lasting and more-difficult-to-abuse version of dextroamphetamine, as the requirement... 

In 2001, Celgene obtained FDA approval to re-launch the single enantiomer dexmethyl-phenidate d-threo 2, formerly Dexedrine ) for ADHD under the brand name Focalin , and subsequently sold the product to Novartis, d-threo Methylphenidate has a 2.2 h... 

The most common treatments for ADHD are the stimulant medications methylphenidate and amphetamines. Secondary medications include dopaminergic or noradrenergic reuptake blockers (e.g., a tamoxetine) and ttj-adrenergic agonists. These treatments are reviewed in this volume (see Chapters 20, 21, 24, and 35). Thus, only brief reference will be made here to the possible effects these compounds may have vis-a-vis modulation of attentional circuits. These ideas are summarized in Figure 8.2. 

Klein et al. (1997) randomized 84 children with CD two-thirds of whom also had ADHD, to placebo or methylphenidate for 5 weeks. Active treatment reduced symptoms of CD the improvement in CD... 

Strattera (package insert). Indianapolis, IN, Eli Lilly and Co, 2005 Swanson JM, Volkow ND Pharmacokinetic and pharmacodynamic properties of stimulants implications for the design of new treatments for ADHD. Behav Brain Res 130 73-78, 2002 Swanson J, Gupta S, Lam A, et al Development of a new once-daily formulation of methylphenidate for the treatment of attention-deficit/hyperac-tivity disorder proof of concept and proof of product studies. Arch Gen Psychiatry 60 204-211, 2003... 

Children with ADHD are inattentive, impulsive, and hyperactive. The areas of their brains that control attention and restraint do not function properly. Stimulant drugs, specifically amphetamines, have been used in the United States to treat children with inattention and hyperactivity disorders since the 1930s. MPH was also discovered to have a calming effect on hyperactive children and a focusing effect on those with attention deficit disorder (ADD). However, it was not until the 1960s that the U.S. Food and Drug Administration (FDA) approved methylphenidate for the treatment of ADHD. At the turn of the twenty-first century, approximately 90% of all methylphenidate was prescribed for ADHD children. Most of the rest was prescribed to treat adults with a sleeping sickness known as narcolepsy. 

A piperidine derivative, methylphenidate facilitates the release of catecholamines and blocks their reuptake and degradation (27). It is considered to be a mild central nervous system (CNS) stimulant, which appears to stimulate brain structures in a manner similar to amphetamines (26). A strongly favored treatment for ADHD, methylphenidate prescriptions account for over 90% of prescription stimulants used in the United States (28). Both children and adults who have been diagnosed with ADHD have been treated with methylphenidate with a high degree of success (29,30). A review of the studies in which stimulants were used by children with ADHD indicated significant evidence for improvement in hyperactivity, inattention, and impulsivity (28). 

Since pemoline is intended primarily as a treatment for ADHD, its effects on vigilance have not been well established. However, Orzack et al. (60) compared 25 mg and 50 mg pemoline to 100 mg and 200 mg caffeine, 15 mg methylphenidate, and placebo on the performance of a 2-hr psychomotor task (pressing keys corresponding to visual stimuli). They found that performance deteriorated as a function of time on task under the influence of placebo, but that 50 mg pemoline, 200 mg caffeine, and 15 mg methylphenidate maintained consistent performance throughout the 2 hr. 

Both affirmations are false. Ritalin is not a safe drug. As the DEA puts it, There is an abundance of scientific literature that indicates that methylphenidate shares the same abuse potential as other Schedule II stimulants. 41 As we have seen in Chapter 3, despite widespread belief to the contrary, there is no proof that ADHD has a biological cause. Even when informed that a biological cause for ADHD has not been found, most people—... 

Nonetheless, the ACNP, an organization of experts beholden to the drug companies, came out spinning on this study, invoking the antiquated, unscientific myth that methylphenidate is specific for ADHD. Unconscionably, they claimed in a press release that the rat study only had implications for normal children and that properly diagnosed ADHD children would not suffer adverse consequences (Lobliner, 2004). 

Q5 Methylphenidate (for example Ritalin) is a CNS stimulant. Treatment can be started at a dose of 5 mg per day and this can be increased by 5 mg every two days. The maximum daily dose should not be more than 60 mg. The last dose should be given four hours before bedtime. This drug is not recommended for children under the age of six years. Treatment of ADHD in Britain is normally initiated in a specialist clinic, after which it may be continued by family doctors. 

Q6 The exact mechanism of action of methylphenidate is not known. However, CNS stimulants generally cause the release of neurotransmitters such as serotonin, dopamine and noradrenaline. The drug is normally used as part of a comprehensive treatment programme for ADHD under specialist supervision. 

For ADHD patients, methylphenidate should generally be discontinued before anticipated pregnancies... 

Structurally-related drugs include dexamfet-amine (used for narcolepsy and in attention deficit hyperactivity disorder (ADHD) see p. 387), methylphenidate (used for ADHD), tenamfetamine (Ecstasy, see p. 189), phentermine, diethylpropion, and pemoline. 

Ambulatory blood pressure monitoring showed changes in blood pressure and heart rate in boys aged 7-11 years taking stimulant therapy (13). This preliminary study with chronic methylphenidate or AdderaU (dex-amfetamine + levamfetamine) for ADHD showed alterations in awake and asleep blood pressures, with profound nocturnal dipping. Modified-release formulations of methylphenidate and AdderaU now allow more sustained blood concentrations in children. The effects of these newer formulations on cardiovascular indices should be evaluated. 

At this time, the preferred first-line drug therapy for ADHD is either methylphenidate, dexmethylphenidate, mixed amphetamine salts, or dextroamphetamine. Atomoxetine, bupropion, or TCAs are good options for those umesponsive to or unable to tolerate stimulants. Clonidine and guanfacine are third-line options or adjuncts that require careful cardiovascular monitoring. Mood stabilizers (e.g., lithium, divalproex, and carbamazepine) and atypical antipsychotics are adjuncts for control of aggression or comorbid bipolar disorder. Other agents require further investigation before their status in the treatment of ADHD can be fuUy determined. 

A good example of the qi/z-Evans aldol reaction is demonstrated by the Novartis synthesis of (+ymethylphenidate 204, a treatment for ADHD in children. Treatment of compound 199 with n-Bu2BOTf and DIPEA followed by aldehyde 200 afforded the 1,2-syn Aldol product 202. Initial Lewis acid complexation followed by deprotonation led to preferential (Z)-enolate formation. In this case, the use of a boron Lewis acid which can only coordinate to two heteroatoms led to syn stereochemistiy governed by a chair-like Zimmerman-Traxler transition state 201 (Scheme 14.72). Following mesylation of the secondary alcohol, the auxiliary was removed under reductive conditions and the resultant alcohol transformed into (-l-)-methylphenidate 204. 

---